Capricor Therapeutics faces class action lawsuit over alleged SEC violations.

Capricor Therapeutics, Inc. is facing a class action lawsuit for allegedly making false and misleading statements about its deramiocel drug candidate's progress towards FDA approval. The lawsuit claims that the company was aware of adverse data but made positive public comments. Shareholders who purchased shares between October 2024 and July 2025 are encouraged to contact the DJS Law Group about possible lead plaintiff appointments. The deadline for joining the lawsuit is September 15, 2025.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a class action lawsuit alleging that the company made false and misleading statements about its lead cell therapy candidate drug deramiocel's progress towards FDA approval. The lawsuit, filed by investors who purchased shares between October 9, 2024, and July 10, 2025, claims that Capricor was aware of adverse data but made positive public comments. Shareholders are encouraged to contact the DJS Law Group about possible lead plaintiff appointments, with a deadline of September 15, 2025.

According to the complaint, defendants provided investors with material information concerning Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). However, the company was also disseminating false and misleading statements and concealing material adverse facts about its four-year safety and efficacy data from the Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA, citing a lack of substantial evidence of effectiveness and the need for additional clinical data. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025.

The lawsuit alleges that these false statements caused shareholders to purchase Capricor's securities at artificially inflated prices, resulting in financial losses. Investors who purchased shares during the class period are encouraged to contact the DJS Law Group to learn more about the class action and the possibility of being appointed as a lead plaintiff. There is no cost or obligation to participate, and any recovery would be shared among class members.